Taysha Gene Therapies is developing an extensive pipeline of potentially curative therapies for monogenic CNS diseases in both rare and large-market indications that are centered on proven AAV technology. Its approach is to combine the speed, scale and expertise of the UT Southwestern Gene Therapy Program with the experience of a proven management team in the gene therapy space. In addition, Taysha is developing a novel AAV capsid platform that utilizes machine learning, DNA shuffling and directed evolution to improve targeted delivery. The company is also developing an AAV redosing platform that facilitates redosing by subverting the humoral immune response through delivery to the vagus nerve.
Taysha currently has 15 AAV gene therapy programs in its pipeline with options to an additional four programs. TGTX-101, a gene replacement therapy for GM2-Gangliosidosis, is expected to advance into clinical development later this year. In total, Taysha is planning to file four Initial New Drug (IND) applications by the end of 2021, including indications for SURF1 deficiency, SLC6A1 haploinsufficiency and Rett syndrome.
Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease.